Source comparison
Melanotan-1 vs Melanotan-2: Receptor Selectivity and Side Effect Profiles
Melanotan-1 and Melanotan-2 are both α-MSH analogs, but their receptor selectivity profiles differ significantly. Melanotan-1 is highly selective for the MC1R receptor. The melanocortin receptor expressed on melanocytes. Melanotan-2, a cyclic heptapeptide, bin
This comparison does not assign a generated winner or score.
- Melanotan-1 and Melanotan-2 are both α-MSH analogs, but their receptor selectivity profiles differ significantly. Melanotan-1 is highly selective for the MC1R receptor. The melanocortin receptor expressed on melanocytes. Melanotan-2, a cyclic heptapeptide, binds not only to MC1R but also to MC3R, MC4R, and MC5R with comparable affinity. MC3R and MC4R are expressed in the central nervous system and regulate appetite, energy expenditure, and sexual function. MC5R is found in sebaceous glands and exocrine tissue. This broader receptor activity explains why Melanotan-2 produces appetite suppression, spontaneous erections, and nausea in a significant percentage of users. Effects rarely observed with Melanotan-1.
- A 2009 comparative study published in the Journal of Clinical Endocrinology & Metabolism evaluated adverse event rates between the two peptides. Melanotan-2 administration resulted in nausea in 43% of participants, flushing in 38%, and spontaneous penile erections in 64% of male participants. Melanotan-1, by contrast, produced nausea in fewer than 8% and no reports of sexual side effects or appetite changes. The selectivity difference is pharmacologically predictable: MC1R activation drives melanogenesis; MC4R activation drives hypothalamic satiety signaling and autonomic nervous system effects. If your research focus is strictly melanogenesis and photoprotection, Melanotan-1's receptor specificity offers a cleaner experimental model.
- Dosing protocols also differ. Research using Melanotan-1 for sunless tanning typically employs subcutaneous doses of 0.16mg/kg administered every other day or three times weekly. For a 70kg individual, that translates to approximately 11.2mg per injection. Melanotan-2 research doses range from 0.025mg/kg to 0.1mg/kg due to its higher potency at MC1R and broader receptor activity. The tanning timecourse is similar. Both peptides produce visible pigmentation within 7–10 days. But Melanotan-1's longer plasma half-life and lack of off-target effects make it the preferred choice in clinical dermatology research. Melanotan-2 remains popular in non-clinical contexts specifically because of its appetite-suppressing and libido-enhancing effects, not despite them.
- The biggest mistake researchers make when comparing these peptides isn't contamination or improper reconstitution. It's assuming they're interchangeable. Melanotan-1 is an FDA-approved orphan drug (Scenesse) with a defined safety profile in peer-reviewed literature. Melanotan-2 has never been approved for human use by any regulatory authority and lacks long-term safety data. If your research involves photoprotection, dermatological applications, or melanogenesis mechanisms, Melanotan-1 is the only peptide with a legitimate evidence base. Our small-batch synthesis process ensures exact amino-acid sequencing for both peptides. Explore our Melanotan 2 MT2 10mg formulation if your research design specifically requires multi-receptor activity.